BDRX, operating in its industry, demonstrates strong performance in debt and liquidity ratios but fails critical Shariah screening due to an exceptionally high interest income ratio of 138.85%, far exceeding the 5% threshold across all standards. Business activities in biopharmaceuticals are permissible, with no non-compliant revenue identified. However, exclusion from all major Shariah indices confirms non-compliance status. Investors should note the need for full purification of any dividends received.